Metformin versus Insulin for the Treatment of Gestational Diabetes
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. METHODS: We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [73]
In the citing paper
“It was concluded that metformin alone, or with supplemental insulin, was not associated with increased perinatal complications.”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [112]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [89]
In the citing paper
“Glyburide is effective in controlling blood glucose in women with gestational diabetes”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Dabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Hoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
An Increase in the Incidence of Gestational Diabetes Mellitus: Northern California, 1991–2000
Ferrara, A., Kahn, H. S., Quesenberry, C. P., Riley, C., & Hedderson, M. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113623.18286.20 · Cited by 452
Glueck, C. J., Phillips, H., Cameron, D., Sieve-Smith, L., & Wang, P. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01666-6 · Cited by 430
Research works printed but not linked: 3
- Coetzee EJ, 1980, S Afr Med J, 58, 795
- Coetzee EJ, 1984, S Afr Med J, 65, 635
- Gutzin SJ, 2003, Can J Clin Pharmacol, 10, 179
Cited by
Items 501–600 of 1,001
A narrative review of metformin in pregnancy: Navigating benefit and uncertainty
McEvoy, R. P., Newman, C., Egan, A. M., & Dunne, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16361 · Cited by 19
“20,21 The aim of this article is to review the evidence for the efficacy and safety of metformin in the various subgroups of pregnant women in which it has been studied, specifically women living with over-weight and obesity, GDM, and pregestational diabetes mellitus (PGDM).”
Screening and management of major endocrinopathies during pregnancy: an update
Paschou, S. Α., Bletsa, E., Papazisi, M., Mili, N., Kanouta, F., Kassi, G., Ψαλτοπούλου, Θ., Goulis, D. G., & Lambrinoudaki, I. V. (2022) · Endocrine · doi:10.1007/s12020-022-03237-y · Cited by 14
Gomes, C. P., Futterman, I. D., Sher, O., Gluck, B., Hillier, T. A., Tehrani, F. R., Chaarani, N., Fisher, N., Berghella, V., & McLaren, R. A. (2024) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2024.101346 · Cited by 17
Caissutti, C., Saccone, G., Ciardulli, A., & Berghella, V. (2017) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13257 · Cited by 13
Inpatient Glycemic Management of the Pregnant Patient
Yeh, T., Yeung, M., & Curanaj, F. A. M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1045-x · Cited by 13
Ouyang, H., & Wu, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01142-7 · Cited by 16
“The included studies were published between 2000 and 2021, with 15 studies [25–30, 46–53, 63] originating from Asia, 7 from North America [31–35, 57, 58], 7 from Europe [36–40, 61, 62], 5 from South America [41–45], 3 from Africa [54–56], and 2 from New Zealand [59, 60].”
Wood, M. E., Patorno, E., Huybrechts, K. F., Bateman, B. T., Gray, K. J., Seely, E. W., Vine, S. M., & Hernández–Díaz, S. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.319 · Cited by 13
Zhang, L., Zhang, X., Guan, L., Daxin, Z., & Ge, J. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2021.2024701 · Cited by 13
“Metformin (DMBG) has been developed as a prospective agent with a good safety pro le that is widely used as a rst-line treatment for type II diabetes and steatohepatitis [2] by controlling insulin [3] and regulating people’s appetite [4].”
BackgroundThomas, N., Jyothirmayi, C. A., Sridhar, S., Kumar, M., Kuruvilla, K. A., & Jana, A. K. (2012) · Indian Pediatrics · doi:10.1007/s13312-013-0096-y · Cited by 13
“Similar findings were noted by two previous RCTs comparing insulin and OHA therapy in GDM [19,22].”
ResultInfluentialSafe prescribing of metformin in diabetes
Davoren, P. M. (2014) · Australian Prescriber · doi:10.18773/austprescr.2014.001 · Cited by 13
Lower treatment targets for gestational diabetes: is lower really better?
Kevat, D., Sinha, A. K., & McLean, A. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.00099 · Cited by 13
Dukhovny, S. E., Bennekom, C. M. V., GAGNON, D. R., Hernández–Díaz, S., Parker, S. E., Anderka, M., Werler, M. M., & Mitchell, A. A. (2018) · Birth Defects Research · doi:10.1002/bdr2.1199 · Cited by 14
Bassiou, W. M. E., Galal, M., & Sherif, L. (2019) · Research Journal of Obstetrics and Gynecology · doi:10.3923/rjog.2019.23.27 · Cited by 14
Cystic Fibrosis-Related Diabetes Mellitus: Etiology, Evaluation, and Management
Fischman, D., & Nookala, V. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1169 · Cited by 13
Stephens, S., Hodson, K. K., & Thomas, S. H. L. (2009) · Medicine · doi:10.1016/j.mpmed.2009.03.010 · Cited by 20
Should metformin be included in fertility treatment of PCOS patients?
Haas, J., & Bentov, Y. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.012 · Cited by 14
Drugs to Control Diabetes During Pregnancy
Feghali, M. N., Umans, J. G., & Catalano, P. M. (2019) · Clinics in Perinatology · doi:10.1016/j.clp.2019.02.005 · Cited by 16
Metformin during Pregnancy in Polycystic Ovary Syndrome: Another Vitamin Bites the Dust
Legro, R. S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2301 · Cited by 15
Paavilainen, E., Niinikoski, H., Parkkola, R., Koskensalo, K., Nikkinen, H., Veijola, R., Vääräsmäki, M., Loo, B.-M., Tossavainen, P. H., Rönnemaa, T., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110780 · Cited by 13
Nanomedicine for Maternal and Fetal Health
Carter, D. M., Better, M., Abbasi, S., Zulfiqar, F., Shapiro, R. L., & Ensign, L. M. (2023) · Small · doi:10.1002/smll.202303682 · Cited by 20
Metformin use in pregnancy: What about long‐term effects in offspring?
Toft, J. H., & Økland, I. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14878 · Cited by 15
“15 During pregnancy, metformin crosses the placenta, and studies have shown similar concentrations in fetal and maternal circulations.”
BackgroundA Systematic Review on Clinical Evidence for Topical Metformin: Old Medication With New Application
Afshar, K., Adibfard, S., Nikbakht, M. H., Rastegarnasab, F., Pourmahdi‐Boroujeni, M., & Abtahi‐Naeini, B. (2024) · Health Science Reports · doi:10.1002/hsr2.70281 · Cited by 12
Potential of Metformin to Improve Cardiac Risk in Postpartum Women with Gestational Diabetes
Viteri, O. A., Sallman, M. A., Berens, P. M., Berens, P., Amro, F. H., Hutchinson, M. S., Ramin, S. M., Blackwell, S. C., Refuerzo, J., & Smith, J. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00180 · Cited by 12
“Studies have shown that metformin is likely safe and does not increase adverse pregnancy outcomes when used to treat GDM (8).”
BackgroundAtal, S., & Dunne, F. (2018) · HRB Open Research · doi:10.12688/hrbopenres.12811.1 · Cited by 13
Pharmacotherapy for hyperglycemia in pregnancy – Do oral agents have a place?
Corcoy, R., Balsells, M., García‐Patterson, A., Shmueli, A., & Hadar, E. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.015 · Cited by 13
Chaves, C., Cunha, F., Martinho, M., Garrido, S., Silva-Vieira, M., Estevinho, C., Melo, A., Figueiredo, O., Morgado, A., Almeida, M. C., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01665-8 · Cited by 12
Thomas, A. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-90988-2_15 · Cited by 12
Effect of maternal pregestational diabetes mellitus on congenital heart diseases
Chen, Z., Mao, S., Guo, L., Qin, J., Yang, L., & Liu, Y. (2022) · World Journal of Pediatrics · doi:10.1007/s12519-022-00582-w · Cited by 16
Yu, Y., Platt, R. W., Reynier, P., Yu, O. H. Y., & Filion, K. B. (2023) · Diabetic Medicine · doi:10.1111/dme.15108 · Cited by 14
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond
Newman, C., Rabbitt, L., Ero, A., & Dunne, F. (2023) · Drugs · doi:10.1007/s40265-023-01899-0 · Cited by 14
“Insulin and sulphonylureas cause maternal hypoglycaemia and weight gain [6, 7], while concern regarding metformin’s impact on foetal size and infant adiposity has limited its use in parts of Europe and the United States [8].”
BackgroundMetformin in Gestational Diabetes Mellitus
Reece, S. W., Parihar, H. S., & LoBello, C. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.4.289 · Cited by 17
Screening, diagnosis and management of gestational diabetes mellitus: A national survey
Sukumaran, S., Madhuvrata, P., Bustani, R., Song, S. H., & Farrell, T. J. (2014) · Obstetric Medicine · doi:10.1177/1753495x14536891 · Cited by 12
Utz, B., Délamou, A., Belaid, L., & Brouwere, V. D. (2016) · Journal of Diabetes Research · doi:10.1155/2016/3217098 · Cited by 15
Screening, Diagnosis and Management of Gestational Diabetes Mellitus
Bhavadharini, B., Ram, U., & Mohan, V. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-023-00376-7 · Cited by 12
Therapy for gestational diabetes mellitus—time for a change?
Damm, P., & Mathiesen, E. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.54 · Cited by 12
Whitelaw, B., & Gayle, C. (2011) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2010.11.001 · Cited by 12
Dunne, F., Newman, C., Alvarez‐Iglesias, A., O’Shea, P. M., Devane, D., Gillespie, P., Egan, A. M., O'Donnell, M. J., & Smyth, A. (2024) · Diabetologia · doi:10.1007/s00125-024-06252-y · Cited by 12
“%) was similar to that reported in the MiG trial (8.5%), which also investigated treatment with 2500 mg/day metformin [15].”
InfluentialMayadunne, T., Saadati, S., Asmelash, D., Mason, T., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16418 · Cited by 17
Kiley, J. W., Hammond, C., Niznik, C. M., RADEMAKER, A. W., Liu, D., & SHULMAN, L. P. (2014) · Contraception · doi:10.1016/j.contraception.2014.08.004 · Cited by 11
Mate, A., Blanca, A. J., Salsoso, R., Toledo, F., Stiefel, P., Sobrevía, L., & Vázquez, C. M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161117666181114125109 · Cited by 11
Effect of a High-Fat Diet and Metformin on Placental mTOR Signaling in Mice
Grace, M. R., Dotters-Katz, S. K., Zhou, C., Manuck, T. A., Boggess, K., & Bae-Jump, V. L. (2019) · American Journal of Perinatology Reports · doi:10.1055/s-0039-1683362 · Cited by 13
Estrella, J. F. G. L., Wiley, V. C., Simmons, D. S., Hng, T., & McLean, M. P. (2021) · Diabetes Care · doi:10.2337/dc21-0327 · Cited by 11
A Review on the Use of Metformin in Pregnancy and Its Associated Fetal Outcomes
Verma, V., & Mehendale, A. M. (2022) · Cureus · doi:10.7759/cureus.30039 · Cited by 12
“As far as pharmaceutical management is concerned, metformin and insulin are frequently prescribed drugs, with metformin being preferred over insulin even though it causes nausea, vomiting, and other gastrointestinal side effects [23].”
BackgroundSato, R., Ikuma, M., Takagi, K., Yamagishi, Y., Asano, J., Matsunaga, Y., & Watanabe, H. (2015) · Medicine · doi:10.1097/md.0000000000000386 · Cited by 11
The care of pregestational and gestational diabetes and drug metabolism considerations
Hedrington, M. S., & Davis, S. N. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1372423 · Cited by 13
“Similarly, in a large trial (n = 751), conducted in Australia and New Zealand, about 46% of women on metformin required addition of insulin [57].”
BackgroundMaple-Brown, L. J., Lindenmayer, G., Barzi, F., Whitbread, C., Connors, C. M., Moore, E., Boyle, J. A., Kirkwood, M., Lee, I., Longmore, D. K., et al. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12905 · Cited by 12
“A large randomized trial comparing metformin to insulin therapy showed no difference in birth weights between those treated with metformin and those treated with insulin.(7) The Clinical Register has provided important epidemiological data in a high-risk population experiencing contextual challenges of socioeconomic d…”
BackgroundInfluentialLawal, S. K., Adeniji, A. A., Sulaiman, S. O., Masud, M. A., Buhari, M. O., & Osinubi, A. A. (2019) · African Health Sciences · doi:10.4314/ahs.v19i3.25 · Cited by 15
Gestational diabetes: costs and consequences
Lindsay, R. S. (2010) · Diabetologia · doi:10.1007/s00125-010-1979-2 · Cited by 13
“A randomised controlled trial showed the efficacy of metformin [6], adding to the older literature on the use of glibenclamide (known as glyburide in the USA and Canada) [7] in GDM.”
BackgroundCrowley, M. T., Paponette, B., Bacon, S., & Byrne, M. M. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1362977 · Cited by 11
Gestational diabetes mellitus diagnosed by screening or symptoms: does it matter?
Hammoud, N. M., de Valk, H. W., Biesma, D. H., & Visser, G. H. A. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2012.722718 · Cited by 12
“However, such a distinction is usually not made in several landmark studies reporting on outcome of GDM [1,2,5].”
BackgroundGlucose Treatment Targets in Pregnancy - A Review of Evidence and Guidelines
Byford, A. R., Forbes, K. A., & SCOTT, E. M. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220422083935 · Cited by 13
Wang, X., Wang, H., Yi, P., Baker, C. K., Casey, G., Xie, X., Luo, H., Cai, J., Fan, X., Soong, L., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110512 · Cited by 10
Hypoglycemics: Pharmacokinetic Considerations During Pregnancy
Klieger, C., Pollex, E. K., Kazmin, A., & Koren, G. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181b385ba · Cited by 12
Diagnosis and Treatment of Hyperglycemia in Pregnancy
Inturrisi, M., Lintner, N. C., & Sorem, K. A. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.09.002 · Cited by 13
“As an alternative to insulin some providers are choosing to use oral medications, such as glyburide and metformin (glucophage), based on studies supporting relative safety and efficacy.(48,49) Langer and colleagues(48) have found that glyburide, a sulfonylurea drug, did not seem to pass through the placenta in the lab…”
BackgroundThe benefit of early treatment without rescreening in women with a history of gestational diabetes
Maher, N., McAuliffe, F. M., & Foley, M. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2012.733772 · Cited by 10
“Agents such as Metformin are in use and studies have shown improved compliance compared with insulin treatment with no significant change in rates of macrosomia or adverse outcomes such as neonatal hypoglycemia [7].”
BackgroundMaternal obesity: how big an impact does it have on offspring prenatally and during postnatal life?
Ford, S. P., & Tuersunjiang, N. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.14 · Cited by 10
Gestational diabetes: emerging concepts in pathophysiology
Hodson, K. K., Robson, S. C., & Taylor, R. (2010) · Obstetric Medicine · doi:10.1258/om.2010.100025 · Cited by 15
Gestational Diabetes Mellitus Update and Review of Literature
Cheung, K. W., & Wong, S.-N. (2018) · Reproductive System & Sexual Disorders · doi:10.4172/2161-038x.s2-008 · Cited by 14
Chiswick, C. A., Reynolds, R. M., Denison, F. C., Drake, A. J., Forbes, S., Newby, D. E., Walker, B. R., Quenby, S. M., Wray, S., Weeks, A. D., et al. (2016) · Efficacy and Mechanism Evaluation · doi:10.3310/eme03070 · Cited by 11
Zhen, X. M., Li, X., & Chen, C. (2018) · Obesity Medicine · doi:10.1016/j.obmed.2018.08.001 · Cited by 12
Renal dysfunction in a mouse model of GDM is prevented by metformin through MAPKs
Liu, Z., Yu, X., Tong, C., & Qi, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10060 · Cited by 11
de Wit, L., Rademaker, D., Voormolen, D. N., Akerboom, B. M. C., Kiewiet, R. M., Soeters, M. R., Verwij-Didden, M. A. L., Assouiki, F., Schippers, D. H., Vermeulen, M. A. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029808 · Cited by 12
“OGLDs are less costly, less burdensome and associated with higher patient satisfaction.(23) 30–33 Metformin has”
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 17
“Some controlled randomized trials are proving limited efficacy of metformin during pregnancy [30, 31].”
BackgroundPregnant women & medical research: a moral imperative
Lyerly, A. D., Faden, R., & Little, M. O. (2009) · Bioethica Forum · doi:10.24894/bf.2009.02020 · Cited by 10
Modelos predictivos de diabetes gestacional, un nuevo modelo de predicción
Fernández, S. C., Martínez, M. D. M., Montero, C. D. F., Rodríguez, I. G., Vilches‐Arenas, Á., & Ortega‐Calvo, M. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.07.014 · Cited by 10
Martine-Edith, G., Johnson, W., Hunsicker, E., Hamer, M., & Petherick, E. S. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053753 · Cited by 10
High-Risk Pregnancy: Management Options
Wildschut, H. I. J., Duvekot, J. J., Cook, J. R., Bacchus, L. J., Bewley, S., Creighton, S., Dear, J., Williams, D., Kilby, M. D., Crouch, N. S., et al. (2017) · Cambridge University Press eBooks · doi:10.1017/9781108349185 · Cited by 11
Mukherjee, M. S., Coppenrath, V. A., & Dallinga, B. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1535 · Cited by 10
“The largest clinical trial to date comparing metformin with insulin was the Metformin in Gestational Diabetes (MiG) trial.(46) In this open-label multicenter randomized clinical trial, 751 women with gestational diabetes during weeks 20–33 of their pregnancy were assigned to either metformin (up to 2500 mg/ day) or in…”
BackgroundMetformin in women at high risk of gestational diabetes mellitus
Brink, H. S., Alkemade, M., van der Lely, A. J., & van der Linden, J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.008 · Cited by 13
Hunt, K. F., Whitelaw, B., & Gayle, C. (2014) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2014.05.005 · Cited by 11
Dornhorst, A., & Banerjee, A. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch53 · Cited by 14
Predictors of metformin monotherapy failure in gestational diabetes mellitus
Silva, V. B., Fonseca, L., Pereira, M. T., Vilaverde, J., Pinto, C., Pichel, F., Almeida, M. D. C., & Dores, J. (2022) · Endocrine Connections · doi:10.1530/ec-21-0540 · Cited by 9
Brzozowska, M. M., Puvanendran, A., Bliuc, D., Zuschmann, A., Piotrowicz, A. K., & O’Sullivan, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1119134 · Cited by 11
“The efficacy of metformin treatment in GDM is not without limitation, as congruent with present study, approximately 14% to 46% of pregnant women fail to achieve adequate glycaemic control with metformin alone (25).”
ResultLovell, H., Mitchell, A., Ovadia, C., Pitrelli, N., Briley, A. L., Singh, C. M., Marschall, H., Cruickshank, K. J., Murphy, H. R., Seed, P. T., et al. (2022) · Trials · doi:10.1186/s13063-022-06462-y · Cited by 11
McGovern, A. P., Hirwa, K. D., Wong, A. K., Holland, C. J. E., Mayne, I. K., Hashimi, A., Thompson, R. C., Creese, V., Havill, S., Sanders, T., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14926 · Cited by 10
Developmental effects of in utero metformin exposure.
Carroll, D. T., Sassin, A. M., Aagaard, K. M., & GANNON, M. A. (2021) · PubMed · Cited by 13
Gerede, A., Domali, E., Chatzakis, C., Margioula‐Siarkou, C., Petousis, S., Stavros, S., Nikolettos, K., Gouveri, E., Sotiriou, S., Tsikouras, P. N., et al. (2025) · Life · doi:10.3390/life15010130 · Cited by 13
Use of antidiabetic agents in the treatment of gestational diabetes mellitus in G ermany, 2008–2012
Heilmaier, C., Thielscher, C., Ziller, M., Altmann, V., & Kostev, K. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12384 · Cited by 10
“Email: kkostev@de.imshealth.com 1592 © 2014 The Authors Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology hypoglycemia, pre-eclampsia, shoulder dystocia, or an increased risk of adiposity and type II diabetes in later life.5–9 As a result of the large-scaled Hyperglycemia…”
BackgroundInfluentialPrise en charge thérapeutique du diabète gestationnel
Jacqueminet, S., & Jannot-Lamotte, M.-F. (2010) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/s0368-2315(10)70051-x · Cited by 17
“La principale étude randomisée (The Metformin in Gestational Diabetes (MiG) trial) [107] (n = 751) (metformine versus l’insuline) retrouvait des complications périnatales comparables dans les 2 groupes (NP1) et une meilleure acceptabilité dans le groupe metformine (NP1), mais l’insuline était indiquée chez 46 % des fe…”
BackgroundKellerer, M., Schäfer-Graf, U. M., & Neonatologie, K. F. (2016) · Cited by 9
Dodd, J. M., Grivell, R. M., Deussen, A. R., Dekker, G., Louise, J., & Hague, W. M. (2016) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-1161-z · Cited by 11
“properties, and is used increasingly in the treatment of gestational diabetes [17].”
BackgroundSelf-citationThe Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy
Blair, R. A., Rosenberg, E. A., & Palermo, N. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1243-1 · Cited by 10
Metabolic Characteristics of Gestational Diabetes Mellitus and the Effects on Pregnancy Outcomes
Luo, P., Fan, Y., Xiong, Y., Zhang, C., Yang, Z., Sun, F., & Mei, B. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s390999 · Cited by 9
Management of gestational diabetes by physicians in Turkey
Akıncı, B., Tosun, P., Bekci, E., Yener, S., Demir, T., & Yeşil, S. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.05.004 · Cited by 11
“[22] J.”
BackgroundClinical presentation and management of diabetes mellitus in pregnancy
Diejomaoh, M., Angelaki, E., Mohammed, A. T., & Al-Azemi, N. (2013) · International Journal of Women s Health · doi:10.2147/ijwh.s52391 · Cited by 13
Bassols, J., Megía, A., Soriano‐Rodríguez, P., Díaz, M., Prats‐Puig, A., Gifre, M., Simón‐Muela, I., Torrent, S., Borrell, A. C., Riera-Socasau, J.-C., et al. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.037 · Cited by 10
Using Oral Agents to Manage Gestational Diabetes: What Have We Learned?
Buschur, E., Brown, F. M., & Wyckoff, J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0570-5 · Cited by 10
Diabetes mellitus in pregnancy, still changing
Hall, D. R., Toit, M. D. D., Mason, D., & Conradie, M. (2015) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2015.1069015 · Cited by 10
Magdy, M. (2014) · Gynecology & Obstetrics · doi:10.4172/2161-0932.1000193 · Cited by 10
“6% with metformin and insulin respectively) [5,16].”
BackgroundResultTREATMENT OF GESTATIONAL DIABETES MELLITUS: INSULIN OR METFORMIN?
Somani, P. S., Sahana, P. K., Chaudhuri, P., & Sengupta, N. (2016) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2016/1011 · Cited by 10
“2%) and in other randomised trials (31-35) only 0-6% of patients had discontinued metformin because of gastrointestinal symptoms.”
InfluentialMetformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions
González, C. D., Alvariñas, J., Bagnes, M. F. G., & Girolamo, G. D. (2018) · Current Clinical Pharmacology · doi:10.2174/1574884714666181224151116 · Cited by 10
The Health of Infants Born to Mothers with Gestational Diabetes Mellitus
Папышева, О. В., Startseva, N. M., Savenkova, I. V., Альбертовна, А. Г., Mayatskaya, T., & Popova, O. A. (2019) · Doctor Ru · doi:10.31550/1727-2378-2019-162-7-12-18 · Cited by 9
Gestational Diabetes and Type 2 Diabetes During Pregnancy
Mukerji, G., Bacon, S., & Feig, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00022-2 · Cited by 13
Costi, L., Lockwood, C. S., Munn, Z., & Jordan, Z. (2014) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2014-1304 · Cited by 9
Endocrine Diseases of Pregnancy
Edlow, A. G., & Norwitz, E. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00027-5 · Cited by 10
GESTATIONAL DIABETES MELLITUS: Challenges in diagnostics, management and impact
de Wit, L. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/195 · Cited by 9
Dasari, P., Gundagurti, B., & Karthikeyan, K. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01048-5 · Cited by 8
Advanced AI-Driven Prediction of Pregnancy-Related Adverse Drug Reactions
Peng, J., Fu, L., Yang, G., & Cao, D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01657 · Cited by 9
Discovering disease-associated drugs using web crawl data
Kim, H., & Park, S. (2016) · ACM Symposium on Applied Computing · doi:10.1145/2851613.2851615 · Cited by 8
“A bleomycin injection is effective and non-toxic treatment in”
Martine‐Edith, G., Johnson, W., & Petherick, E. (2023) · Diabetic Medicine · doi:10.1111/dme.15204 · Cited by 11
“…evidence has suggested that women prescribed combined pharmaceutical treatment have higher baseline BMI or severity of hyperglycaemia than women prescribed metformin alone, 4,20 which may reflect a number of factors including differences in health behaviours between the two treatment groups.”
Background
Metadata
- Authors
- Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P.
- Affiliations
- Auckland City Hospital (NZ)
- Women's and Children's Hospital (AU)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Christchurch Hospital (NZ)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-08
- Volume
- 358
- Issue
- 19
- Pages
- 2003-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003621575
- Cited by
- 1,291
- References
- 33
- Citations by year
- 2026: 49 · 2025: 60 · 2024: 52 · 2023: 65 · 2022: 63 · 2021: 90 · 2020: 67 · 2019: 66 · 2018: 105 · 2017: 125 · 2016: 68 · 2015: 82 · 2014: 69 · 2013: 62 · 2012: 56
- FWCI
- 78.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, neonatal hypoglycemia, perinatal complications, maternal glycemic control, postpartum glucose tolerance, treatment acceptability, treatment preferences, neonatal respiratory distress, phototherapy
- MeSH terms
- Adult, Drug Therapy, Combination, Female, Gestational Age, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Jaundice, Neonatal, Metformin, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Diabetes, Gestational, Patient Satisfaction, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.